

A Message from Our CEO and Board of Directors President

Twenty years ago, a small but determined group of advocates dared to imagine a world where neuroendocrine cancer would no longer go unrecognized, underfunded, and undertreated. In 2025, that vision moved towards reality, and this community is the reason why. Today, NETRF stands as the global force in neuroendocrine cancer research funding and a leader in patient education, at the forefront of a worldwide movement to overcome this disease. Our twentieth anniversary year brought with it some of the most meaningful milestones in our history, and we are deeply grateful to share them with you.

Research is at the heart of everything we do. In 2025, NETRF awarded \$3 million in grants to fund 15 innovative projects, bringing together the brightest scientific minds working to unravel the origins of neuroendocrine cancers and lay the foundation for the therapies and cures patients need. Every dollar entrusted to us by our donors carries a big responsibility — and a powerful expression of our collective hope for the future. Your generosity is also fueling the momentum of our five-year *Breakthroughs Today, Cures Tomorrow* campaign in ways that have truly moved us. In just the first year, we reached 31% of our five-year goal. This is a remarkable achievement that speaks to the urgency and support of this community. The pace you have set gives us every reason for confidence and excitement about what lies ahead.

At the same time, we never lose sight of the people at the center of this mission. Each day, we have the privilege of connecting with patients and their loved ones. These connections remind us, always, of why this work matters.

As we look to the future, we are profoundly grateful for your support. Together, we will build on this progress to improve the lives of neuroendocrine cancer patients and their loved ones, and we are honored to walk alongside each of you on this journey.

Elyse Gellerman, MHS
Chief Executive Officer

Josh Mailman, MBA, FSNMMI
President, Board of Directors